版本:
中国

BRIEF-Chemocentryx says granted EU orphan drug designation for avacopan in treating patients with C3G

May 23 Chemocentryx Inc

* Says granted EU orphan drug designation for avacopan in treatment of debilitating kidney disease C3 glomerulopathy

* Says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in mid-2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐